With an eye to 'non-obvious binding sites,' CBC Group launches precision medicine play with $67M and ex-Editas exec at the helm

Over the past year, CBC Group has been quietly incubating a biotech to take advantage of the AI rush and make some new therapies against …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

With an eye to 'non-ob­vi­ous bind­ing sites,' CBC Group launch­es pre­ci­sion med­i­cine play with $67M and ex-Ed­i­tas ex­ec at the helm